These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3480081)

  • 61. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
    Hempel G; Flege S; Würthwein G; Boos J
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):133-41. PubMed ID: 11862427
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
    Liliemark JO; Gahrton G; Paul CY; Peterson CO
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
    Cortes J; Faderl S; Estey E; Kurzrock R; Thomas D; Beran M; Garcia-Manero G; Ferrajoli A; Giles F; Koller C; O'Brien S; Wright J; Bai SA; Kantarjian H
    J Clin Oncol; 2005 Apr; 23(12):2805-12. PubMed ID: 15728224
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Intra-arterial infusion of adriamycin in the treatment of locally advanced breast cancer].
    Yayoi E; Inaji H; Maeura Y; Mori T; Takatsuka Y
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2751-9. PubMed ID: 6508325
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
    Ochs J; Sinkule JA; Danks MK; Look AT; Bowman WP; Rivera G
    J Clin Oncol; 1984 Oct; 2(10):1092-7. PubMed ID: 6593435
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
    Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
    J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sequential vincristine, arabinosylcytosine and adriamycin in acute leukemia: cytologic and cytokinetic studies.
    Riccardi A; Mazzini G; Montecucco C; Cresci R; Traversi E; Berzuini C; Ascari E
    Cytometry; 1982 Sep; 3(2):104-9. PubMed ID: 7140479
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM.
    Genne P; Duchamp O; Solary E; Pinard D; Belon JP; Dimanche-Boitrel MT; Chauffert B
    Leukemia; 1994 Jan; 8(1):160-4. PubMed ID: 8289482
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.
    Nooter K; Sonneveld P; Martens A
    Cancer Res; 1985 Sep; 45(9):4020-5. PubMed ID: 4027999
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
    Paul C; Tidefelt U; Liliemark J; Peterson C
    Leuk Res; 1989; 13(2):191-6. PubMed ID: 2927175
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
    Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
    J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.
    Iguchi H; Tone H; Ishikura T; Takeuchi T; Umezawa H
    Cancer Chemother Pharmacol; 1985; 15(2):132-40. PubMed ID: 4017162
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases].
    Wang SQ
    Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):71-3. PubMed ID: 1889343
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interaction of antileukemia agents adriamycin and daunomycin with sphinganine on the differentiation of human leukemia cell line HL-60.
    Yung BY; Luo KJ; Hui EK
    Cancer Res; 1992 Jul; 52(13):3593-7. PubMed ID: 1617630
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Quercetin alleviates myocyte toxic and sensitizes anti-leukemic effect of adriamycin.
    Han Y; Yu H; Wang J; Ren Y; Su X; Shi Y
    Hematology; 2015 Jun; 20(5):276-83. PubMed ID: 25201038
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.